Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph F Merola

Showing results (371-380 of 394) with videos related to

Pageof 40
Sort By:
Journal of the American Academy of Dermatology|November 19, 2025
Joint position statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on routine testing for latent tuberculosis infection prior to and during treatment of psoriasis patients with interleukin 17 or interleukin 23 inhibitorsAndrew Blauvelt, Bruce E Strober, Guy S Eakin, et al.
Dermatology and Therapy|January 13, 2022
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 TrialDiamant Thaçi, Bruce Strober, Kenneth B Gordon, et al.
The British Journal of Dermatology|August 28, 2025
SPECTREM Phase 3b Clinical Trial Results Through Week 16: Guselkumab Efficacy and Safety for the Treatment of Low Body Surface Area, Moderate Psoriasis With High-Impact Site InvolvementLinda Stein Gold, Alice B Gottlieb, April W Armstrong, et al.
The Journal of Investigative Dermatology|May 18, 2026
AI versus Experts: Navigating Challenging Cases in Psoriatic DiseaseLourdes M Pérez-Chada, Victoria Garfinkel, Beth A Childs, et al.
RMD Open|February 22, 2024
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITALLaura C Coates, Robert Landewé, Iain B McInnes, et al.
Lancet (London, England)|December 10, 2022
Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)Joseph F Merola, Robert Landewé, Iain B McInnes, et al.
Arthritis Care & Research|October 20, 2019
Development of a Set of Lupus-Specific, Ambulatory Care-Sensitive, Potentially Preventable Adverse Conditions: A Delphi Consensus StudyCandace H Feldman, Cameron Speyer, Rachel Ashby, et al.
Journal of Drugs in Dermatology : JDD|December 5, 2023
International Dermatology Outcome Measures (IDEOM) - Report from the 2022 Annual MeetingKathryn Lee, Michael J Woodbury, Melissa Peri Zundell, et al.
JAMA Dermatology|June 22, 2018
Dietary Recommendations for Adults With Psoriasis or Psoriatic Arthritis From the Medical Board of the National Psoriasis Foundation: A Systematic ReviewAdam R Ford, Michael Siegel, Jerry Bagel, et al.
BMJ Open|December 23, 2022
Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trialRebecca H Haberman, Katrina A MacFarlane, Sydney Catron, et al.
Pageof 40

Showing results (371-380 of 394) with videos related to

Sort By:
Pageof 40
Journal of the American Academy of Dermatology|November 19, 2025
Joint position statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on routine testing for latent tuberculosis infection prior to and during treatment of psoriasis patients with interleukin 17 or interleukin 23 inhibitorsAndrew Blauvelt, Bruce E Strober, Guy S Eakin, et al.
Dermatology and Therapy|January 13, 2022
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 TrialDiamant Thaçi, Bruce Strober, Kenneth B Gordon, et al.
The British Journal of Dermatology|August 28, 2025
SPECTREM Phase 3b Clinical Trial Results Through Week 16: Guselkumab Efficacy and Safety for the Treatment of Low Body Surface Area, Moderate Psoriasis With High-Impact Site InvolvementLinda Stein Gold, Alice B Gottlieb, April W Armstrong, et al.
The Journal of Investigative Dermatology|May 18, 2026
AI versus Experts: Navigating Challenging Cases in Psoriatic DiseaseLourdes M Pérez-Chada, Victoria Garfinkel, Beth A Childs, et al.
RMD Open|February 22, 2024
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITALLaura C Coates, Robert Landewé, Iain B McInnes, et al.
Lancet (London, England)|December 10, 2022
Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)Joseph F Merola, Robert Landewé, Iain B McInnes, et al.
Arthritis Care & Research|October 20, 2019
Development of a Set of Lupus-Specific, Ambulatory Care-Sensitive, Potentially Preventable Adverse Conditions: A Delphi Consensus StudyCandace H Feldman, Cameron Speyer, Rachel Ashby, et al.
Journal of Drugs in Dermatology : JDD|December 5, 2023
International Dermatology Outcome Measures (IDEOM) - Report from the 2022 Annual MeetingKathryn Lee, Michael J Woodbury, Melissa Peri Zundell, et al.
JAMA Dermatology|June 22, 2018
Dietary Recommendations for Adults With Psoriasis or Psoriatic Arthritis From the Medical Board of the National Psoriasis Foundation: A Systematic ReviewAdam R Ford, Michael Siegel, Jerry Bagel, et al.
BMJ Open|December 23, 2022
Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trialRebecca H Haberman, Katrina A MacFarlane, Sydney Catron, et al.
Pageof 40